Also known as: H.C. Wainwright, HC Wainwright
H.C. Wainwright is a full-service investment bank focused on healthcare and life sciences. It provides corporate finance, strategic advisory, and institutional sales and trading services.
Iovance Biotherapeutics reported Q4 2025 revenue of $87 million, beating estimates, while receiving FDA fast-track designation for lifileucel in non-small cell lung cancer and reporting strong sarcoma trial data.
Multiple analysts have raised price targets on Praxis Precision Medicines, with Wolfe Research initiating coverage at $500 and Guggenheim increasing its target to $800, citing strong market potential for ulixacaltamide in essential tremor.
